<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00937092</url>
  </required_header>
  <id_info>
    <org_study_id>LUH-DC-101-FT</org_study_id>
    <nct_id>NCT00937092</nct_id>
  </id_info>
  <brief_title>Dopamine in Acute Decompensated Heart Failure (DAD-HF) Trial</brief_title>
  <acronym>DAD-HF</acronym>
  <official_title>Comparison of High-dose Furosemide Versus the Combination of Low-dose Furosemide and Low-dose Dopamine in Patients With Acute Decompensated Heart Failure</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Larissa University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Larissa University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of this study is to compare the effects of high-dose furosemide versus low-dose
      furosemide combined with low-dose dopamine on diuresis, renal function, electrolyte balance,
      and 60-day post-discharge outcomes in patients hospitalized with acute decompensated heart
      failure.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Worsening renal function (WRF) and hypokalemia related to diuretic use for acute
      decompensated heart failure (ADHF) are common and portend poor prognosis. Low dose dopamine
      infusion improves renal perfusion. Whether dopamine infusion improves diuresis and/or reduces
      renal complication in ADHF is not known. The aim of this study is to compare the effects of
      high-dose furosemide (HDF, 40 mg furosemide bolus IV, followed by continuous IV infusion of
      20 mg/h for a total of 8 hours) vs. low-dose furosemide combined with low-dose dopamine
      (LDFD, 40 mg furosemide bolus IV, followed by continuous IV infusion of 5 mg/h furosemide
      plus 5μg/kg/min dopamine for a total of 8 hours) on diuresis, renal function, electrolyte
      balance, and 60-day post-discharge outcomes in patients hospitalized with ADHF.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2009</start_date>
  <completion_date type="Anticipated">July 2012</completion_date>
  <primary_completion_date type="Anticipated">January 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-year mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).</measure>
    <time_frame>1-year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>60-day mortality or rehospitalization (all-cause, cardiovascular, non-cardiovascular, and due to worsening heart failure).</measure>
    <time_frame>60 days post discharge</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Acute Heart Failure</condition>
  <arm_group>
    <arm_group_label>High-dose furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High-dose furosemide (HDF): 20 mg/h continuous IV administration for 8 hours</description>
  </arm_group>
  <arm_group>
    <arm_group_label>low-dose dopamine + low-dose furosemide</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Furosemide</intervention_name>
    <description>High-dose furosemide(HDF, furosemide 20 mg/h intravenously)</description>
    <arm_group_label>High-dose furosemide</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>low-dose dopamine + low-dose furosemide</intervention_name>
    <description>low-dose furosemide combined with low-dose dopamine (LDFD, furosemide 5 mg/h plus dopamine 5μg/kg/min intravenously)</description>
    <arm_group_label>low-dose dopamine + low-dose furosemide</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients with New York Heart Association (NYHA) functional class IV heart failure
             according to the American Heart Association (AHA) classification, namely dyspnea on
             minimal exertion or rest dyspnea, orthopnea, and paroxysmal nocturnal dyspnea

          -  signs of congestion (third heart sound or pulmonary rales on physical examination)

          -  pulmonary congestion on chest x-ray

          -  serum B-type natriuretic peptide levels &gt; 400 pg/ml or NT-proBNP &gt; 1500 pg/ml

          -  echocardiographic documentation of systolic or diastolic dysfunction

          -  all candidate patients must be:

          -  Age &gt;18 years old

          -  on medical therapy with an ACE-inhibitor and/or a β-blocker

          -  experiencing an acute decompensation of known chronic HF

          -  Having baseline oxygen saturation &lt;90% on admission arterial blood gas

        Exclusion Criteria:

          -  the investigators will exclude patients with:

               -  acute de novo HF

               -  severe renal failure (serum creatinine &gt; 200 μmol/L or GFR &lt; 30 ml/min/1.73m2)

               -  admission systolic blood pressure &lt; 90 mm Hg

               -  severe valvular disease

               -  known adverse reactions to furosemide or dopamine

               -  HF secondary to congenital heart disease

               -  a scheduled procedure with a need for IV contrast dye

               -  a scheduled cardiac surgery within 6 months
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory Giamouzis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larissa University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Filippos Triposkiadis, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Larissa University Hospital</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Filippos Triposkiadis, MD</last_name>
    <phone>+30 2410682821</phone>
    <email>ftriposkiadis@yahoo.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gregory Giamouzis, MD</last_name>
    <phone>+30 6937212670</phone>
    <email>ggiamou@emory.edu</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Department of Cardiology, Volos General Hospital</name>
      <address>
        <city>Volos</city>
        <state>Magnesia</state>
        <zip>382 21</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Themistoklis Tsaknakis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Nastas, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Themistoklis Kyrlidis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Department of Cardiology, Larissa University Hospital</name>
      <address>
        <city>Larissa</city>
        <zip>411 10</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Gregory Giamouzis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Filippos Triposkiadis, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>John Skoularigis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitrios Economou, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>George Karayannis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Dimitrios Rovithis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Charalambos Parisis, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Greece</country>
  </location_countries>
  <verification_date>May 2010</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 29, 2009</study_first_submitted>
  <study_first_submitted_qc>July 9, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 10, 2009</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 26, 2010</last_update_posted>
  <responsible_party>
    <name_title>Gregory Giamouzis, MD</name_title>
    <organization>Department of Cardiology, Larissa University Hospital</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>Dopamine</keyword>
  <keyword>Furosemide</keyword>
  <keyword>Worsening Renal Function</keyword>
  <keyword>Hypokalemia</keyword>
  <keyword>Outcomes</keyword>
  <keyword>Prognosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Dopamine</mesh_term>
    <mesh_term>Dopamine Agents</mesh_term>
    <mesh_term>Furosemide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

